These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 14726314)

  • 1. Recipients of blood or blood products "at vCJD risk".
    Bird SM
    BMJ; 2004 Jan; 328(7432):118-9. PubMed ID: 14726314
    [No Abstract]   [Full Text] [Related]  

  • 2. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variant Creutzfeldt-Jakob disease in a transfusion recipient: coincidence or cause?
    Chohan G; Llewelyn C; Mackenzie J; Cousens S; Kennedy A; Will R; Hewitt P
    Transfusion; 2010 May; 50(5):1003-6. PubMed ID: 20230536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood supplies hit by vCJD fear.
    Strachan-Bennett S
    Nurs Times; 2004 Jan 6-12; 100(1):6. PubMed ID: 14735624
    [No Abstract]   [Full Text] [Related]  

  • 5. Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products.
    Millar CM; Makris M
    Br J Haematol; 2012 Aug; 158(4):442-52. PubMed ID: 22775486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients informed of increased risk of vCJD contact.
    Kmietowicz Z
    BMJ; 2004 Sep; 329(7468):702. PubMed ID: 15388598
    [No Abstract]   [Full Text] [Related]  

  • 7. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
    Flan B; Arrabal S
    Transfus Clin Biol; 2007 May; 14(1):51-62. PubMed ID: 17540602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The risk of prion contamination through the transfusion of cellular products].
    Lefrère JJ
    Transfus Clin Biol; 2007 May; 14(1):25-34. PubMed ID: 17499536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Theoretical risk of vCJD transmission via blood transfusion. Leukocyte and erythrocyte depletion of the transfusion blood is a practice in many countries].
    Andersen O
    Lakartidningen; 2002 Mar; 99(12):1310-4. PubMed ID: 11998162
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of vCJD on blood supply.
    Seitz R; von Auer F; Blümel J; Burger R; Buschmann A; Dietz K; Heiden M; Hitzler WE; Klamm H; Kreil T; Kretzschmar H; Nübling M; Offergeld R; Pauli G; Schottstedt V; Volkers P; Zerr I
    Biologicals; 2007 Apr; 35(2):79-97. PubMed ID: 17320412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of prion filtration of red blood cells to reduce the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease in the Republic of Ireland.
    Teljeur C; Flattery M; Harrington P; O'Neill M; Moran PS; Murphy L; Ryan M
    Transfusion; 2012 Nov; 52(11):2285-93. PubMed ID: 22486387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prion diseases.
    Knight R
    Vox Sang; 2004 Jul; 87 Suppl1():104-6. PubMed ID: 15200617
    [No Abstract]   [Full Text] [Related]  

  • 13. Blood transfusion and spread of variant Creutzfeldt-Jakob disease.
    Dietz K; Raddatz G; Wallis J; Müller N; Zerr I; Duerr HP; Lefèvre H; Seifried E; Löwer J
    Emerg Infect Dis; 2007 Jan; 13(1):89-96. PubMed ID: 17370520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panel Discussion. Millennium Festival of Medicine--Transfusion 2020--18 October 2000.
    Fogden M; Whitehorn K; Starr D; Persaud R; Hannaford R; Barbara J; Love E; Robinson A; Ferguson E; Turner G; Wallington T; Klein H; Franklin I; Fry R
    Transfus Med; 2001 Apr; 11(2):136-45. PubMed ID: 11583001
    [No Abstract]   [Full Text] [Related]  

  • 15. A retrospective case note review of deceased recipients of vCJD-implicated blood transfusions.
    Gillies M; Chohan G; Llewelyn CA; MacKenzie J; Ward HJ; Hewitt PE; Will RG
    Vox Sang; 2009 Oct; 97(3):211-8. PubMed ID: 19671123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aspects of the risks associated with vCJK from plasma derivatives from human plasma].
    Burger R; Offergeld R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jun; 52(6):648-9. PubMed ID: 19557456
    [No Abstract]   [Full Text] [Related]  

  • 17. The quandary of Creutzfeldt-Jakob disease.
    Larke B
    CMAJ; 1998 Oct; 159(7):789-92. PubMed ID: 9805025
    [No Abstract]   [Full Text] [Related]  

  • 18. Transfusion-related vCJD: prevention strategies for prion transmission.
    Holland PV
    Lijec Vjesn; 2007 May; 129 Suppl 3():46. PubMed ID: 18959066
    [No Abstract]   [Full Text] [Related]  

  • 19. [vCJD epidemiology in France].
    Brandel JP; Salomon D; Alpérovitch A
    Transfus Clin Biol; 2006 Nov; 13(5):304-6. PubMed ID: 17188544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience.
    Dolan G
    Haemophilia; 2006 Mar; 12 Suppl 1():16-20; discussion 26-8. PubMed ID: 16445813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.